Quality of Life and Fixed-ratio Combination of Insulin Degludec and Liraglutide (iDegLira)

NCT04190160 · Completed

Last updated 2026-05-28

This clinical trial tests a fixed-dose combination of two diabetes medications (insulin degludec and liraglutide) in adults with type 2 diabetes to see how it affects their overall quality of life.

Status Completed The study has finished.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design open-label (no blinding) treatment study

Participants 35 people

Who can join Ages 75–99 · all sexes Healthy volunteers accepted.

Timeline Started 2018-11 · est. completion 2021-03

Where 1 site · Italy

What this study is testing ClinicalTrials.gov NCT04190160 ↗

Description as written by the study sponsor.

This work is aimed at improving the quality of life of older patients affected by type 2 diabetes. The investigators will try to amiliorate the complexity of hypogliceamic treatment in a little group of older patients with type 2 diabetes reducing the number of pills and/or insulin administration using a single daily dose of a fixed combination of insulin degludec and liraglutide. This therapeutic semplification will be done indipendently of pre-existent glicaemic control.

Treatments tested

IDegLira Drug

A single administration of IDegLira, dose depending on glicaemic control, in place of any pre-existing hipoglycaemic therapeutic scheme

Main thing measured	Self reported quality of Life (CASP-19)
Sponsor	Stefano Rizza
Conditions studied	Type2 Diabetes
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04190160 ↗